Production (Stage)
Cardiff Oncology, Inc.
CRDF
$3.86
$0.051.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -34.19% | -26.24% | -21.83% | -5.63% | 10.80% |
| Total Depreciation and Amortization | -3.39% | -6.80% | -5.61% | 7.14% | 162.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 26.86% | 48.58% | 70.19% | -21.43% | 7.44% |
| Change in Net Operating Assets | -176.48% | -72.83% | -80.25% | -46.11% | -32.17% |
| Cash from Operations | -65.30% | -43.82% | -31.41% | -29.42% | 10.61% |
| Capital Expenditure | -- | 100.00% | 100.00% | 100.00% | -900.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -409.25% | -66.76% | -328.09% | 19.43% | -35.72% |
| Cash from Investing | -414.58% | -66.74% | -346.90% | 22.04% | -36.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.20% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.20% | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -813.41% | 498.44% | -201.33% | 57.24% | -125.34% |